ConcertAI Appoints Shawn W. Bates as General Manager, Commercial Solutions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2026--

ConcertAI ®, the real‑world healthcare intelligence company for those advancing research, treatment, and care in oncology and other complex diseases, today announced the appointment of Shawn W. Bates as general manager of Commercial Solutions. In this role, Bates will lead and scale ConcertAI's Commercial Solutions business, helping accelerate measurable impact for life sciences customers and the patients they serve.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512392612/en/

Drawing on nearly 30 years of commercial and general management leadership across AI, SaaS, real-world data, and life sciences, Bates will lead the strategy to scale and expand the business, including its recently launched Cadence Suite ™, which streamlines patient journey management by identifying friction early. Bates will also align Sales, Product, Delivery, and Customer Success around shared performance goals to ensure predictable execution and successful product adoption.

"Shawn brings the rare combination of commercial leadership, AI fluency, and deep real-world evidence expertise that our Commercial Solutions business needs at this stage of growth," said Eron Kelly, CEO of ConcertAI. "His proven track record of scaling SaaS and data-driven businesses and partnering with the world's leading life sciences companies makes him the ideal leader to expand the reach and impact of our commercial offerings. We're excited to welcome Shawn to the team and look forward to the value he and his organization will deliver for our customers.”

Across his career, Bates has led global commercial organizations totaling more than $280 million for some of the most recognized companies in life sciences and healthcare technology. He brings deep expertise across real-world evidence, HEOR, market access, medical affairs, integrated drug development, regulatory science, and commercialization.

"I'm honored to join Eron and the leadership team at such a pivotal moment in the company's growth, and I look forward to scaling our Commercial Solutions business and accelerating measurable impact for our customers and the patients who ultimately benefit from their therapies,” said Bates. “ConcertAI's combination of best-in-class real-world data, agentic AI capabilities, and deep oncology and life sciences expertise represents exactly the kind of platform that can deliver transformational outcomes for life sciences partners.”

Most recently, Bates served as Chief Revenue Officer at ProductLife Group, where he led commercial functions and business unit leadership across integrated product development and regulatory solutions, life cycle maintenance, medical and RWE, market access, and digital and AI innovation. Previously, Bates was Chief Commercial Officer at OM1, where he led commercial strategy, sales, marketing, operations, strategic alliances, pricing, and contracting for the AI and real-world data company. Earlier, Bates served as VP, Global Head of Commercial at Certara and VP, Global Commercial Leader at IQVIA, with additional senior leadership tenures at Awen International, Dentsply Sirona, and Eli Lilly.

Bates began his career as a U.S. Army Intelligence officer, serving nearly a decade and exiting with the rank of Captain. He holds a B.S. in Electrical and Computer Science Engineering from The Citadel and an MBA, and is a Lean Six Sigma Master Black Belt. He has also served in advisory roles for the Cancer Research Institute and the National Pediatric Cancer Foundation, supporting industry advocacy efforts for patients with difficult-to-treat diseases.

About ConcertAI
ConcertAI provides purpose-built, enterprise artificial intelligence and real-world data solutions for life sciences and healthcare organizations, turning complex health data into actionable insights that advance research and care. Its proprietary Precision Suite SaaS solution and CARA platform deliver agentic AI capabilities designed for healthcare’s biggest challenges and are trained specifically for life sciences use cases like translational medicine, clinical development, clinical trials and commercial acceleration. Working with 75% of the top 30 life sciences organizations, more than 2,000 healthcare providers and medical societies, and a broad network of industry partners, ConcertAI has built the market’s most comprehensive clinicogenomic datasets to fuel drug development, trial acceleration, and advance clinical care. Through our data, AI technology, partnerships, and expertise, we empower oncologists and radiologists with real-time clinical insights at the point of care for better patient outcomes, and equip researchers with solutions to accelerate life-changing therapies to patients. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, and Tokyo. Learn more at concertai.com.

ConcertAI Appoints Shawn W. Bates as General Manager, Commercial Solutions

BALTIMORE (AP) — Federal prosecutors announced criminal charges Tuesday in the 2024 collapse of Baltimore’s Francis Scott Key Bridge, accusing the Singapore-based operator of a ship and a key employee of making critical decisions that led to the ship crashing into the span and killing six people.

Acting Attorney General Todd Blanche called it a “preventable tragedy of enormous consequence.”

The indictment names Synergy Marine Pte Ltd., based in Singapore, and Synergy Maritime Pte Ltd., based in Chennai, India. Radhakrishnan Karthik Nair, 47, an Indian national who was technical superintendent for the Dali container ship, was also charged.

The Dali lost power twice in a four-minute span as it moved to sea from the Port of Baltimore, causing it to crash into the Key Bridge on March 24, 2024. Investigators say a loose wire in a switchboard likely caused the first power loss.

If the Dali had used the proper fuel supply pumps, according to the indictment, the vessel would have regained power in time to safely get under the bridge. It crashed instead, killing six construction workers who had been filling potholes.

“As alleged, the bridge was struck and collapsed because those who were responsible for the ship’s operation deliberately cut corners at the expense of safety,” said Jimmy Paul, head of the FBI’s Baltimore office.

The companies and Nair are charged with conspiracy, willfully failing to immediately inform the U.S. Coast Guard of a known hazardous condition, obstruction of an agency proceeding and false statements. Messages seeking comment were not immediately returned.

The Synergy companies are also charged with misdemeanors for the release of pollutants into the Patapsco River, including shipping containers and their contents.

The FBI investigation into the crash focused on the vessel’s operations and whether the crew knew of critical systems issues before leaving port.

The National Transportation Safety Board found last year that two electrical blackouts — one caused by the loose wire and another by problems with a fuel pump — disabled the controls of the huge cargo ship before it crashed into the bridge.

The Dali was leaving Baltimore bound for Sri Lanka when its steering failed because of the power loss. The ship crashed into a supporting column of the bridge at about 1:30 a.m.

Maryland officials estimate it could cost between $4.3 billion and $5.2 billion to replace the bridge, which is expected to be open to traffic in late 2030.

“The altered skyline is a constant reminder of this tragedy,” Paul said.

But the true cost of the collapse was far greater, according to the Maryland Attorney General’s Office. It halted shipping at the Port of Baltimore, disrupted the livelihoods of thousands, rerouted road traffic through communities already bearing disproportionate burdens and triggered economic problems statewide.

The indictment comes on the heels of a settlement in principle between the State of Maryland, Synergy Marine and Grace Ocean Private Limited, the Singapore-based ship owner, Attorney General Anthony Brown announced in April.

That lawsuit alleged the crash was the result of negligence, mismanagement and the reckless operation of a vessel that was not seaworthy and should never have left port. Plaintiffs include the families of the six construction workers who died, owners of cargo that was on the ship and local governments seeking damages for economic losses. The details of the settlement haven’t been disclosed and some portions of the lawsuit remain unresolved.

The state sought damages on behalf of its agencies for the destruction of the bridge, harm to the Patapsco River and surrounding environment, lost revenues and economic losses to Maryland and its residents.

The settlement does not resolve any claims the state has against the shipbuilder, Hyundai, the attorney general’s office said in April.

The bridge, a longstanding Baltimore landmark, was a vital piece of transportation infrastructure that allowed drivers to easily bypass downtown. The original 1.6-mile (2.6-kilometer) steel span took five years to build and opened to traffic in 1977.

White reported from Detroit.

FILE - The cargo ship Dali is stuck under part of the Francis Scott Key Bridge after the ship hit the bridge, March 26, 2024, as seen from Pasadena, Md. (AP Photo/Mark Schiefelbein, File)